title: The promise of microRNA replacement therapy.
abstract: MicroRNAs (miRNA), a class of natural RNA-interfering agents, have recently been identified as attractive targets for therapeutic intervention. The rationale for developing miRNA therapeutics is based on the premise that aberrantly expressed miRNAs play key roles in the development of human disease, and that correcting these miRNA deficiencies by either antagonizing or restoring miRNA function may provide a therapeutic benefit. Although miRNA antagonists are conceptually similar to other inhibitory therapies, restoring the function of a miRNA by miRNA replacement is a less well characterized approach. Here, we discuss the specific properties of miRNA replacement and review recent examples that explored the therapeutic delivery of miRNA mimics in animal models of cancer.
authors.affiliation: Mirna Therapeutics, Inc. and Asuragen, Inc., Austin, TX 78744, USA. abader@mirnarx.com
authors.forename: Andreas G
authors.initials: AG
authors.lastname: Bader
authors.forename: David
authors.initials: D
authors.lastname: Brown
authors.forename: Matthew
authors.initials: M
authors.lastname: Winkler
mesh_terms: D000818:Animals; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D035683:MicroRNAs / Q000008:administration & dosage* / Q000037:antagonists & inhibitors / Q000235:genetics; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*
chemical_list: D035683:MicroRNAs
references.citation: Nat Rev Cancer. 2001 Nov;1(2):130-41
references.pmid: 11905804
references.citation: Cell. 2007 Dec 14;131(6):1109-23
references.pmid: 18083101
references.citation: Nat Genet. 2007 May;39(5):673-7
references.pmid: 17401365
references.citation: Cell. 2005 Mar 11;120(5):635-47
references.pmid: 15766527
references.citation: Nat Rev Cancer. 2007 Nov;7(11):819-22
references.pmid: 17914404
references.citation: Cancer Res. 2007 Aug 15;67(16):7713-22
references.pmid: 17699775
references.citation: Nature. 2005 Jun 9;435(7043):834-8
references.pmid: 15944708
references.citation: Cell. 2009 Jun 12;137(6):1005-17
references.pmid: 19524505
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8
references.pmid: 18308936
references.citation: Cancer Cell. 2006 Mar;9(3):189-98
references.pmid: 16530703
references.citation: Nat Rev Cancer. 2006 Apr;6(4):259-69
references.pmid: 16557279
references.citation: Expert Opin Biol Ther. 2006 Jan;6(1):55-61
references.pmid: 16370914
references.citation: Nature. 2008 Sep 11;455(7210):148
references.pmid: 18784686
references.citation: Cell Cycle. 2008 Mar 15;7(6):759-64
references.pmid: 18344688
references.citation: Mol Ther. 2010 Jan;18(1):181-7
references.pmid: 19738602
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: PLoS One. 2009 Aug 28;4(8):e6816
references.pmid: 19714243
references.citation: Oncogene. 2010 Mar 18;29(11):1580-7
references.pmid: 19966857
references.citation: Cancer Res. 2010 Jul 15;70(14):5923-30
references.pmid: 20570894